This pathway is also an important target for cancer treatment, including mammalian target of rapamycin (mTOR) inhibitors, inhibitors of PI3K and inhibitors of Akt that have already demonstrated clinical efficacy for different tumors [24]. This evidence concerns the gene AKT1 and cancer.